Patient organisations warned the European Council yesterday (12 April) to be “vigilant” in the relocation of the European Medicines Agency (EMA), as well as avoid unnecessary delays that may cause disruptions in healthcare.
The British government’s triggering of Article 50 has heated up the discussion about the relocation of the EMA from London.
Contacted by EURACTIV.com, a European Commission spokesperson said that the decision on an agency’s seat is determined “by common agreement between the representatives of the member states meeting at Heads of State or Government level or by the Council”.
The 2012 Joint Statement and Common Approach on EU decentralised agencies, which was endorsed by the European Parliament, the Council and the Commission, sets out a number of criteria to be taken into account in order to contribute to the decision-making process for choosing an agency’s seat. Ler mais (...)